Open Access. Powered by Scholars. Published by Universities.®
- Publication
- File Type
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Nadolol In Pregnancy: A Medical Student’S Reflection On Her Pregnancy, Rebecca King-Mallory, Shawndra Barker, Kaitlin Mcgrogan, Adam M. Franks
Nadolol In Pregnancy: A Medical Student’S Reflection On Her Pregnancy, Rebecca King-Mallory, Shawndra Barker, Kaitlin Mcgrogan, Adam M. Franks
Adam M. Franks, MD
Hypertension is a common concern during pregnancy. Beta-blockers are one potential treatment, but third trimester exposure has correlated with an increased risk of perinatal events. Nadolol, a nonselective beta blocker, has properties that differ from those of its selective counterparts, including longer half-life, decreased protein binding, and renal excretion in the unchanged form. There is very limited data on the use of nadolol during pregnancy, and its safety has not been completely evaluated. This case study documents the perinatal outcomes of nadolol use throughout a medical student’s pregnancy and explores the experience in obtaining and undergoing medical care.
Teratogen Use In Women Of Childbearing Potential: An Intervention Study, Karie Morical-Kline, Alison Walton, Tracey Guildenbecher
Teratogen Use In Women Of Childbearing Potential: An Intervention Study, Karie Morical-Kline, Alison Walton, Tracey Guildenbecher
Alison M. Walton
Purpose: The purpose of this study was to quantify the number of women of childbearing potential who are prescribed angiotensin-converting enzyme inhibitor (ACE inhibitor), angiotensin receptor blocker (ARB), or HMG-coenzyme A reductase inhibitor (statin) and to determine the number of documented teratogenic risk discussions (risk documentation) before and after educational interventions. Methods: The institutional review board–approved retrospective chart review included female patients ages 15 to 45 years who were prescribed an ACE inhibitor, ARB, or statin between January 1, 2007, and March 1, 2009. Exclusion criteria were tubal ligation and hysterectomy. A survey determined physician knowledge of teratogenic risks and …
Angiotensin-Converting Enzyme Inhibitor, Angiotensin-Receptor Blocker, And Hmg-Coa Reductase Inhibitor Use In Women Of Childbearing Potential [Abstract 217e], Alison Walton, Kelsey Morrical-Kline, Tracey Guildenbecher
Angiotensin-Converting Enzyme Inhibitor, Angiotensin-Receptor Blocker, And Hmg-Coa Reductase Inhibitor Use In Women Of Childbearing Potential [Abstract 217e], Alison Walton, Kelsey Morrical-Kline, Tracey Guildenbecher
Alison M. Walton
Poster presented at the 31st ACCP Annual Meeting, Austin, Texas; October 2010.